Clinical trials: Mental Disorder
Schizophrenia, Schizoaffective Disorder
A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.
The purpose of this study is to document the long-term safety of 25, 37.5, or 50 mg long-acting injectable risperidone given via injection to the gluteal muscle every 2 weeks to subjects with schizophrenia or schizoaffective…
- Trial name
- NCT00495118
- Testing
- risperidone
- Volunteers
- 314 people
- Sponsor
- Janssen, LP
Restless Legs Syndrome
Cross-Sectional Study: Prevalence of Restless Legs Syndrome in Patients With Unpleasant Sensations of the Legs
The proposed study is a Cross-sectional epidemiological study, performed in 330 primary care practices in Germany. The study will be conducted on a fixed day in November 2007.
- Trial name
- NCT00557258
- Where
- 251 sites in Germany
- Volunteers
- 14,956 people
- Sponsor
- Boehringer Ingelheim
Anxiety Disorders, Major Depressive Disorder
Acquisition and Analysis of Relationships Between Longitudinal Emotional Signals Produced by an Artificial Intelligence Algorithm and Self-questionnaires Used in the Psychiatric Follow-up of Patients With Mood and/or Anxiety Disorders: a Real-Environment Study.
The worldwide prevalence of anxiety and depression increased massively during the pandemic, with a 25% rise in the number of patients suffering from psychological distress.
- Trial name
- EMOACQ-1 (NCT05988840)
- Testing
- Acquisition and analysis of relationships between Longitudinal Emotional Signals produced by a software and Self-questionnaires.
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Emobot
Schizophrenia
A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to document the long-term safety and tolerability of risperidone, formulated as a long-acting injectable, in the treatment of patients with schizophrenia or schizoaffective disorder; in addition, to…
- Trial name
- NCT00210691
- Testing
- Risperidone
- Volunteers
- 273 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Stroke Sequelae, Cognitive Impairment
Remote Bimanual Virtual Rehabilitation Post CVD
The aim of the study is to develop the BrightBrainer G (grasp), a game-based upper-extremity motor and cognitive rehabilitation system using custom virtual reality simulations.
- Conditions
- Stroke Sequelae, Cognitive Impairment, Depression
- Trial name
- NCT04713384
- Testing
- Integrative tele-rehalitation of chronic stroke survivors using custom therapeutic games
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Grigore Burdea
Schizophrenia
Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia
To assess the effectiveness of aripiprazole once-monthly in the maintenance treatment of patients with a diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text…
- Trial name
- NCT01795547
- Testing
- Aripiprazole and aripiprazole once-monthly, Paliperidone and paliperidone palmitate
- Where
- 2 sites in United States
- Volunteers
- 295 people
- Sponsor
- H. Lundbeck A/S
Alzheimer Disease
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
This study will evaluate the safety and tolerability of bapineuzumab when administered by subcutaneous injection. The study is open only to subjects who participated in the preceding double-blind study (3133L1-2203 US).
- Trial name
- NCT00916617
- Testing
- bapineuzumab
- Where
- 16 sites in United States
- Volunteers
- 62 people
- Sponsor
- Pfizer
Anxiety, Stress
A Clinical Trial of De-stress and Focus Capsule in the Management of Stress.
The current study focuses in clinical validation of the efficacy of nutraceutical product in the management of mental focus and cognition. The benefits of these nutraceuticals extend beyond mere cognitive enhancement.
- Conditions
- Anxiety, Stress, Stuporous
- Trial name
- NCT06569849
- Testing
- De-Stress and Focus capsule- U001, De-Stress and Focus capsule - I001
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Herbolab India Pvt. Ltd.
Alzheimer's Disease
Computer-Based Training for Mild Alzheimer's Disease
The primary objective of this study is to evaluate the effects of computer-based training program ("HiFi-AD") on the memory and cognitive abilities of individuals diagnosed with mild Alzheimer's Disease (AD).
- Trial name
- NCT00319891
- Testing
- Computer-based Cognitive Training
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Posit Science Corporation
Constipation, Signs and Symptoms, Digestive
Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients
To characterize the pharmacokinetics (PK) of naloxegol after single oral dose and through population PK in paediatric patients with opioid induced constipation (OIC) or at risk of OIC.
- Trial name
- NCT02099591
- Testing
- Naloxegol
- Where
- 16 sites in Denmark, Israel and 3 more
- Volunteers
- 61 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Generalized Anxiety Disorder
Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in adults with generalized anxiety disorder.
- Trial name
- NCT00730691
- Testing
- Vortioxetine, Duloxetine
- Where
- 66 sites in United States
- Volunteers
- 781 people
- Sponsor
- Takeda
Major Depressive Disorder
Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
To examine the efficacy and safety of aripiprazole versus placebo as an adjunctive therapy co-administered with either an selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) in…
- Trial name
- NCT00876343
- Testing
- Aripiprazole (Fixed dose), Aripiprazole (Titrated dose)
- Where
- 8 sites in Japan
- Volunteers
- 586 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Bipolar Disorder, Bipolar Depression
A Study To Investigate The Antidepressant Effect Of Lamotrigine In Patients With Bipolar Disorder Using Lithium
This is a study that, in the first 16 weeks, investigates whether lamotrigine versus placebo offers effect on depressive episodes for patients with bipolar disorder (also known as manic depressive disorder) who use lithium.
- Trial name
- NCT00224510
- Testing
- lamotrigine
- Where
- 31 sites in Netherlands, Spain
- Volunteers
- 120 people
- Sponsor
- GlaxoSmithKline
Tourette Syndrome
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
This is a Phase 2b, randomized, double-blind, placebo-controlled, dose-optimization study to evaluate the efficacy, safety, and tolerability of NBI-98854 titrated to the subject's optimal dose administered once daily (qd) for a…
- Trial name
- NCT03325010
- Testing
- Valbenazine
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 127 people
- Sponsor
- Neurocrine Biosciences
Major Depressive Disorder
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01435759
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg
- Where
- 82 sites in United States, Argentina and 3 more
- Volunteers
- 1,197 people
- Sponsor
- Shire
Quality of Life (QOL), Anxiety
Testing the Efficacy of the "Syd" App on Improving Quality of Life and Mental Health Among University Students in the Kingdom of Saudi Arabia
The goal of this clinical trial is to learn if using the "See Yourself Differently" (syd) app can help improve quality of life and mental health for university students in Saudi Arabia.
- Conditions
- Quality of Life (QOL), Anxiety, Stress, Affect (Mental Function)
- Trial name
- NCT06979778
- Testing
- See Yourself Differently (syd) mobile app
- Where
- Saudi Arabia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- iamYiam Limited
Alzheimer Disease
Neuro RX Gamma - Pivotal Phase
The active Neuro RX Gamma device uses non-invasive near-infrared energy delivered to the brain with the intention to improve cognitive functioning and quality of life in patients with moderate to severe Alzheimer's Disease.
- Trial name
- NCT03484143
- Testing
- Active Neuro RX Gamma device
- Where
- 9 sites in United States, Canada
- Volunteers
- 228 people
- Sponsor
- Vielight Inc.
Schizophrenia
Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)
Schizophrenia is a brain disease. The primary features of schizophrenia are characterized by Positive symptoms (symptoms that should not be there, inability to think clearly, to distinguish reality from fantasy i.e., hearing…
- Trial name
- NCT00156091
- Testing
- Olanzapine, Asenapine
- Volunteers
- 260 people
- Sponsor
- Organon and Co
Depression, Anxiety
Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy
A randomized controlled trial comparing pharmacogenomic guided versus standard pharmacist care to optimize antidepressant drug therapy.
- Conditions
- Depression, Anxiety, Major Depressive Disorder, Generalized Anxiety Disorder
- Trial name
- NCT03591224
- Testing
- Pharmacogenomic Testing, Pharmacist Standard of Care
- Where
- 2 sites in Canada
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- John Papastergiou Pharmacy Ltd
Anxiety
Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325
The study is carried out in order to determine the relationship between the dose of AZD7325 and the blood concentration of AZD7325, and to investigate to which extent AZD7325 binds to the GABAA receptors.
- Trial name
- PET (NCT00681720)
- Testing
- AZD7325, Radioligand (11C) flumazenil
- Where
- Sweden
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- AstraZeneca